Patents by Inventor Qingjun Zhou

Qingjun Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12324769
    Abstract: A preparation method of a double-network versatile hydrogel with antibacterial and drug sequential release capabilities is provided in the present disclosure, belonging to the technical field of biological corneas. The preparation method includes the following steps: mixing filipin protein-methacrylate, glycidyl methacrylate functionalized quaternized chitosan, polydeoxyribonucleotide, and lithium phenyl(2,4,6-trimethylbenzoyl) phosphinate with drug-loaded micelles, followed by cross-linking under irradiation of ultraviolet to construct a double-network versatile hydrogel with antibacterial and drug sequential release capabilities.
    Type: Grant
    Filed: October 11, 2024
    Date of Patent: June 10, 2025
    Assignee: EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY
    Inventors: Hengrui Zhang, Qingjun Zhou, Shuqin Meng, Huifang Ren
  • Patent number: 12319947
    Abstract: A method for preparing (S)-nicotine by reduction includes conducting a reduction process on an alkene compound as shown in Formula I and/or an iminium cation compound as shown in Formula II, thereby producing (S)-nicotine. The method is simple, safe, reliable, and yields both high purity and high quantities of (S)-nicotine production.
    Type: Grant
    Filed: November 28, 2023
    Date of Patent: June 3, 2025
    Assignee: PORTON PHARMA SOLUTIONS LTD.
    Inventors: Wenqing Lin, Hongjie Zheng, Xiaobo Liu, Zecong Chen, Lingyu Li, Qingjun Zhou, Songhe Wang, Yongtang Yue, Jicheng Hu, Yue Zhang, Shanshan Miao
  • Publication number: 20250170305
    Abstract: A transparent sclera-based corneal repair material, and a preparation method and use thereof, belonging to the technical field of medical repair materials are disclosed. The sclera, a natural biological material that is convenient to obtain, is used as a source of the corneal repair material. The opaque sclera is hyalinized by compressing. Carboxyl groups on a scleral fibrin are activated by cross-linking, such that amino groups of the sclera combine with the carboxyl groups to form an amide bond. The amide bond belongs to a covalent bond and has a desirable stability, thereby maintaining a transparency of the sclera after the compressing. Therefore, the transparent sclera can be used as a transparent corneal tissue repair material.
    Type: Application
    Filed: January 9, 2023
    Publication date: May 29, 2025
    Inventors: Weiyun SHI, Qingjun ZHOU, Long ZHAO, Xiuli SUN, Zhen SHI
  • Publication number: 20250169985
    Abstract: A preparation method of a double-network versatile hydrogel with antibacterial and drug sequential release capabilities is provided in the present disclosure, belonging to the technical field of biological corneas. The preparation method includes the following steps: mixing filipin protein-methacrylate, glycidyl methacrylate functionalized quaternized chitosan, polydeoxyribonucleotide, and lithium phenyl(2,4,6-trimethylbenzoyl) phosphinate with drug-loaded micelles, followed by cross-linking under irradiation of ultraviolet to construct a double-network versatile hydrogel with antibacterial and drug sequential release capabilities.
    Type: Application
    Filed: October 11, 2024
    Publication date: May 29, 2025
    Applicant: Eye Institute of Shandong First Medical University
    Inventors: Hengrui ZHANG, Qingjun ZHOU, Shuqin MENG, Huifang REN
  • Publication number: 20250165669
    Abstract: The present disclosure provides a method for building a finite element model of corneal endothelial cells, including: importing a standard corneal model into finite element pre-processing software, and generating 2D meshes, to obtain a basic mesh model; importing a detailed geometric model of corneal endothelial cells; determining a complete corneal endothelial cell model according to the basic mesh model and the detailed geometric model; and performing calculation according to the complete corneal endothelial cell model. The present disclosure can improve the efficiency and effect of building a finite element model of corneal endothelial cells.
    Type: Application
    Filed: November 5, 2023
    Publication date: May 22, 2025
    Applicant: Shandong First Medical University Affiliated Eye Institute (SHANDONG EYE INSTITUTE/QINGDAO EYE HOS
    Inventors: Lixin Xie, Dongfang Li, Zongyi Li, Qingjun Zhou, Ping Lin, Xinhang Wang, Chaoying Wang
  • Patent number: 12106970
    Abstract: The present disclosure discloses a pattern sheet, a semiconductor intermediate product, and a hole etching method. The pattern sheet includes a substrate, a dielectric layer, and a mask structure. The mask structure includes a multi-layer mask layer. An uppermost mask layer is a photoresist layer. A thickness of each layer of the mask layer and etching selectivity ratios between the layers below the mask layer satisfy that in each two neighboring layers of the mask layer, a lower layer of the mask layer is etched to form a through-hole penetrating a thickness of the lower layer of the mask layer, a remaining thickness of the upper layer of the mask layer is greater than or equal to zero.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: October 1, 2024
    Assignee: BEIJING NAURA MICROELECTRONICS EQUIPMENT CO., LTD.
    Inventors: Qiushi Xie, Xiaoping Shi, Qingjun Zhou, Dongsan Li, Chun Wang, Yiming Zhang
  • Patent number: 12090156
    Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 17, 2024
    Assignee: INSTITUTE OF OPHTHALMOLOGY AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG INSTITUTE OF OPHTHALMO
    Inventors: Weiyun Shi, Qingjun Zhou, Hongwei Wang, Bining Zhang
  • Patent number: 12076443
    Abstract: A preparation method of a nanozyme composite-based hybrid hydrogel eye drop includes synthesizing a tannin-coordinated silver/cobalt composite nanoparticle through a coordination reaction of cobalt chloride hexahydrate with ammonia water and an oxidation-reduction reaction of silver nitrate with tannin; and mixing the silver/cobalt composite nanoparticle with an acrylate-modified gelatin, conducting an ultrasonic treatment to allow complete dissolution, and irradiating a resulting mixture under ultraviolet (UV) light to obtain the nanozyme composite-based hybrid hydrogel eye drop. The preparation method of the present disclosure has simple operations and a short preparation time. The eye drop prepared by the preparation method shows a broad-spectrum bactericidal effect against a variety of bacteria and fungi, and has prominent preventive and therapeutic effects for bacterial and drug-resistant bacterial corneal infections.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 3, 2024
    Assignee: INSTITUTE OF OPHTHALMOLOGY AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG INSTITUTE OF OPHTHALMOLOGY, QINGDAO EYE HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY)
    Inventors: Qingjun Zhou, Weiyun Shi, Hongwei Wang, Fangying Song
  • Publication number: 20240261281
    Abstract: In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.
    Type: Application
    Filed: February 15, 2023
    Publication date: August 8, 2024
    Applicant: Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute of
    Inventors: Weiyun SHI, Qingjun ZHOU, Hongwei WANG, Bining ZHANG
  • Publication number: 20240261231
    Abstract: A preparation method of a nanozyme composite-based hybrid hydrogel eye drop includes synthesizing a tannin-coordinated silver/cobalt composite nanoparticle through a coordination reaction of cobalt chloride hexahydrate with ammonia water and an oxidation-reduction reaction of silver nitrate with tannin; and mixing the silver/cobalt composite nanoparticle with an acrylate-modified gelatin, conducting an ultrasonic treatment to allow complete dissolution, and irradiating a resulting mixture under ultraviolet (UV) light to obtain the nanozyme composite-based hybrid hydrogel eye drop. The preparation method of the present disclosure has simple operations and a short preparation time. The eye drop prepared by the preparation method shows a broad-spectrum bactericidal effect against a variety of bacteria and fungi, and has prominent preventive and therapeutic effects for bacterial and drug-resistant bacterial corneal infections.
    Type: Application
    Filed: February 15, 2023
    Publication date: August 8, 2024
    Applicant: Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute of
    Inventors: Qingjun ZHOU, Weiyun SHI, Hongwei WANG, Fangying SONG
  • Publication number: 20240266182
    Abstract: The present disclosure discloses a pattern sheet, a semiconductor intermediate product, and a hole etching method. The pattern sheet includes a substrate, a dielectric layer, and a mask structure. The mask structure includes a multi-layer mask layer. An uppermost mask layer is a photoresist layer. A thickness of each layer of the mask layer and etching selectivity ratios between the layers below the mask layer satisfy that in each two neighboring layers of the mask layer, a lower layer of the mask layer is etched to form a through-hole penetrating a thickness of the lower layer of the mask layer, a remaining thickness of the upper layer of the mask layer is greater than or equal to zero.
    Type: Application
    Filed: April 2, 2021
    Publication date: August 8, 2024
    Inventors: Qiushi XIE, Xiaoping SHI, Qingjun ZHOU, Dongsan LI, Chun WANG, Yiming ZHANG
  • Publication number: 20240226177
    Abstract: Retinal pigment epithelial cells can be used for replacing corneal endothelial cells, preventing and treating diseases or symptoms such as corneal endothelial functional decompensation. The retinal pigment epithelial cell transplantation, e.g., to the anterior chamber of an eye of the subject, can restore corneal transparency, reduce corneal thickness, reconstruct corneal endothelial barrier function, effectively treat corneal endothelial functional decompensation and corneal endothelial dysfunction.
    Type: Application
    Filed: February 29, 2024
    Publication date: July 11, 2024
    Inventors: Weiyun Shi, Qingjun Zhou, Zongyi Li, Chunxiao Dong, Haoyun Duan
  • Publication number: 20240216375
    Abstract: A sympathetic activation inhibitor and/or an ?1-adrenergic receptor inhibitor in preparing a medicine for treating dry eyes and belonging to the technical field of medicines for treating dry eyes, and a use of a sympathetic activation inhibitor and/or an ?1-adrenergic receptor inhibitor in preparing a medicine for treating or relieving dry eye syndrome. The medicine prepared by the use can antagonize an ?1-adrenergic receptor (including an ?1a-adrenergic receptor) or inhibit sympathetic activation, and can relieve and treat dry eye symptoms.
    Type: Application
    Filed: August 18, 2022
    Publication date: July 4, 2024
    Inventors: Lixin Xie, Qingjun Zhou, Mingli Qu, Sai Zhang
  • Publication number: 20240156854
    Abstract: The present disclosure provides a methylcobalamin ophthalmic preparation and a preparation method and use thereof, belonging to the technical field of eye drops. The methylcobalamin ophthalmic preparation includes a methylcobalamin technical (TC) and proanthocyanidin, where the methylcobalamin TC and the proanthocyanidin have a mass ratio of (0.02-0.1):(0-0.5); and a dosage form of the methylcobalamin ophthalmic preparation is one or more of a drop, a hydrogel, and a liposome. In the present disclosure, the methylcobalamin is used as an active ingredient, and the proanthocyanidin is used as a synergist of the methylcobalamin; the methylcobalamin ophthalmic preparation can promote corneal nerve regeneration, accelerate corneal epithelial healing, and effectively inhibit corneal neovascularization to improve corneal perception.
    Type: Application
    Filed: April 3, 2023
    Publication date: May 16, 2024
    Inventors: Weiyun Shi, Bi Ning Zhang, Shijiu Chen, Qingjun Zhou, Hongwei Wang
  • Publication number: 20240123120
    Abstract: A corneal implant with adhesion-increase treatment is associated with a method for increasing the adhesion of the artificial corneal implant by an epoxy-amine ring-opening reaction of the polyamino high-molecular polymer and glycidyl methacrylate to obtain a methacrylate modified polyamino polymer. The method improves the adhesion and biocompatibility of the artificial corneal endothelial sheet by photo-initiated free radical polymerization reaction, and has a high oxygen permeability and a high adhesion. It can be used for treating patients with corneal endothelial decompensation, playing a barrier role to block aqueous humor, eliminating corneal edema, and reducing the risk of corneal graft detachment after surgery.
    Type: Application
    Filed: July 13, 2022
    Publication date: April 18, 2024
    Inventors: Weiyun SHI, Ting WANG, Qingjun ZHOU, Xiaoyu ZHANG, Hongwei WANG
  • Publication number: 20240124908
    Abstract: A method for preparing (S)-nicotine by reduction includes conducting a reduction process on an alkene compound as shown in Formula I and/or an iminium cation compound as shown in Formula II, thereby producing (S)-nicotine. The method is simple, safe, reliable, and yields both high purity and high quantities of (S)-nicotine production.
    Type: Application
    Filed: November 28, 2023
    Publication date: April 18, 2024
    Inventors: Wenqing LIN, Hongjie ZHENG, Xiaobo LIU, Zecong CHEN, Lingyu LI, Qingjun ZHOU, Songhe WANG, Yongtang YUE, Jicheng HU, Yue ZHANG, Shanshan MIAO
  • Publication number: 20240016852
    Abstract: The present invention discloses the application of retinal pigment epithelial cells for replacing corneal endothelial cells, preventing and treating diseases or symptoms such as corneal endothelial functional decompensation. The retinal pigment epithelial cell suspension provided by the present invention can restore corneal transparency, reduce corneal thickness, reconstruct corneal endothelial barrier function, effectively treat corneal endothelial functional decompensation, and has a wide range of application values and positive social benefits for the treatment or recovery of people with visual impairment due to corneal injury.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 18, 2024
    Inventors: Weiyun Shi, Qingjun Zhou, Zongyi Li, Chunxiao Dong, Haoyun Duan
  • Patent number: 11761003
    Abstract: Long-chain non-coding RNA NEAT1 are used in the preparation of drugs for the treatment of Fuchs' endothelial corneal dystrophy. Overexpression of the long-chain non-coding RNA NEAT1 can effectively reduce corneal endothelial damage, alleviate the symptoms of corneal edema, can be used for the treatment of Fuchs' endothelial corneal malnutrition.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: September 19, 2023
    Assignee: Eye Institute of Shandong First Medical University
    Inventors: Weiyun Shi, Qun Wang, Qingjun Zhou, Shengqian Dou, Hui Jiang, Bin Zhang
  • Publication number: 20230181496
    Abstract: The present disclosure provides use of a norepinephrine or a ?-adrenergic receptor inhibitor in the preparation of a medicament for nerve injury repair in diabetes, and belongs to the technical field of nerve repair drugs. By inhibiting norepinephrine secretion or antagonizing ?2-adrenergic receptors, the present disclosure promotes the expression of neurotrophic factors in epithelial cells to further regulate nerve repair. Therefore, the present disclosure provides the use of a norepinephrine inhibitor or a ?-adrenergic receptor inhibitor in the preparation of a medicament for nerve injury repair in diabetes. The inhibitor provided by the present disclosure features excellent stability and low cost, and has excellent clinical application prospects.
    Type: Application
    Filed: May 4, 2022
    Publication date: June 15, 2023
    Inventors: Qingjun ZHOU, Ya LI, Xingyue YUAN
  • Publication number: 20230110021
    Abstract: A composite hydrogel contains alginate hydrogel and acellular matrix hydrogel. The ingredients used to produce the acellular matrix hydrogel contains acellular matrix and transglutaminases (TGases). The alginate hydrogel contains salginate complex. The alginate hydrogel and acellular matrix hydrogel constitute a three-dimensional crosslinking structure. The TGases can catalyze isopeptide bonding between acellular matrixes, and thus forms acellular matrix hydrogel through crosslinking.
    Type: Application
    Filed: October 5, 2022
    Publication date: April 13, 2023
    Inventors: Weiyun SHI, Qingjun ZHOU, Long ZHAO, Zhen SHI